跳至主要内容
临床试验/JPRN-jRCT1080223956
JPRN-jRCT1080223956已完成4 期

Phase IV clinical trial of CEDARCURE(R)SLIT-tablet and MITICURE(R)SLIT-tablet. - Evaluation of safety in patients with both Japanese cedar pollinosis and HDM-induced allergic rhinitis.

TORII PHARMACEUTICAL CO., LTD.0 个研究点目标入组 109 人开始时间: 2018年6月25日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
109

研究概览

简要总结

There were no events requiring attention to the concurrent use of CEDARCURE and MITICURE in addition to CEDARCURE or MITICURE monotherapy. Furthermore, there was no difference in the safety profile during the combined therapy with CEDARCURE and MITICURE after CEDARCURE monotherapy and after MITICURE monotherapy.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 5age old 至 <= 64age old(—)
性别
All

入选标准

  • 1) Patients with both cedar pollen and HDM-specific IgE : class 2 or more.
  • 2) Patients who have a clinical history of cedar pollinosis in 2017 and 2018 cedar pollen seasons.
  • 3) Patients with positive nasal provocation test (HDM).

排除标准

  • 1) Patients who have received specific immunotherapy for cedar pollinosis or HDM in history.
  • 2) Patients who have severe asthma.
  • 3) Patients who have food allergy, drug allergy or oral allergy syndrome.

研究者

相似试验